Anne Moscona MD
Professor of Pediatrics; of Microbiology/Immunology; of Physiology/Biophysics
Join to View Full Profile
701 West 168th StHammer Health Sciences 13-06New York, NY 10032
Dr. Moscona is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalFellowship, Infectious Disease, 1985 - 1988- Icahn School of Medicine at Mount Sinai/Kravis Children'sResidency, Pediatrics, 1982 - 1985
Columbia University Vagelos College of Physicians and SurgeonsClass of 1982
Harvard CollegeBA, Biochemistry & Molecular Biology, 1974 - 1978
Certifications & Licensure
NY State Medical License 1985 - 2027
American Board of Pediatrics Pediatrics
Publications & Presentations
PubMed
- Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development.Ariel J Kuhn, Victor K Outlaw, Tara C Marcink, Zhen Yu, Megan C Mears
Journal of Virology. 2025-03-18 - Development of nebulized inhalation delivery for fusion-inhibitory lipopeptides to protect non-human primates against Nipah-Bangladesh infection.Olivier Reynard, Mathieu Iampietro, Claire Dumont, Sandrine Le Guellec, Stephanie Durand
Antiviral Research. 2025-03-01 - 1 citationsIntranasally administrated fusion-inhibitory lipopeptides block SARS-CoV-2 infection in mice and enable long-term protective immunity.Said Mougari, Valérie Favède, Camilla Predella, Olivier Reynard, Stephanie Durand
Communications Biology. 2025-01-15
Press Mentions
- CUIMC Update - March 15, 2021March 15th, 2021
The in Vitro Multilineage Differentiation and Maturation of Lung and Airway Cells from Human Pluripotent Stem Cell–Derived Lung Progenitors in 3DMarch 1st, 2021
Preparing for a New Normal, Researchers Study Molecular Basis for COVID Drug Similar to TamifluDecember 4th, 2020- Join now to see all
Grant Support
- Vaccines and Therapeutic Antibodies to Respiro, Rubula, Peribunya and Phenuiviridae (R2P2)-ReVAMPPWASHINGTON UNIVERSITY2024–2027
- Broad spectrum inhibitors of paramyxovirus envelope proteinsCOLUMBIA UNIVERSITY HEALTH SCIENCES2023–2027
- Broad spectrum inhibitors of paramyxovirus envelope proteinsCOLUMBIA UNIVERSITY HEALTH SCIENCES2023–2027
- Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2COLUMBIA UNIVERSITY HEALTH SCIENCES2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
